Cathie Wood的ARK ETF資本以Coinbase（Coin）和Robinhood（Hood）股票的回調資本

輸入：Cathie Wood的ARK ETFS資本以Coinbase（Coin）和Robinhood（Hood）股票的回調資源為

Cathie Wood's ARK ETFs on Thursday capitalized on the pullback in Coinbase (NASDAQ:COIN) and Robinhood (NASDAQ:HOOD) stocks to load up additional shares.

凱茜·伍德（Cathie Wood）的ARK ETF週四大利用Coinbase（NASDAQ：COIN）和Robinhood（NASDAQ：HOOD）股票的回調，以加載額外的股票。

The ARK Innovation Fund (ARKK) bought 29,353 new shares of Coinbase at $191.8 per share for a total of $5.63 million. The move comes following Coinbase's exclusion from the S&P 500 Index (SPX) and the broader weakness in the crypto markets.

ARK Innovation Fund（ARKK）以每​​股191.8美元的價格購買了29,353股Coinbase的新股，總計563萬美元。此舉是在Coinbase排除在標準普爾500指數（SPX）和加密市場中更廣泛的弱點之後的。

Coinbase shares are trading lower by 58% year-to-date and down 64% over the past 12 months. At current levels, analysts see 68% potential downside.

在過去的12個月中，Coinbase股票的交易額降低了58％，下降了64％。在目前的水平上，分析師看到68％的潛在缺點。

Earlier this week, ARKK ETF had acquired 52,573 shares of the crypto platform, and the ARK Fintech Innovation ETF (ARKF) bought 11,605 shares.

本週早些時候，ARKK ETF收購了Crypto平台的52,573股，ARK Fintech Innovation ETF（ARKF）購買了11,605股。

Another notable trade made yesterday was the purchase of 143,855 shares of Robinhood Markets (NASDAQ:HOOD) at $39.07 per share for a total of $5.6 million. Earlier this week, the ARKK ETF purchased 269,864 shares of HOOD stock.

昨天進行的另一個值得注意的交易是購買143,855股Robinhood Markets（NASDAQ：HOOD），每股39.07美元，總計560萬美元。本週早些時候，ARKK ETF購買了269,864股Hood股票。

Additionally, the ARKK ETF and the ARK Genomic Revolution ETF (ARKG) bought a total of 105,974 CRISPR Therapeutics (NASDAQ:CRSP) shares for $4.6 million and 80,975 GitLab (NASDAQ:GITL) shares for $4.27 million.

此外，ARKK ETF和ARK Genomic Revolution ETF（ARKG）以460萬美元和80,975 Gitlab（NASDAQ：GITL）的股份以42.7萬美元的價格購買了105,974 CRISPR Therapeutics（NASDAQ：CRSP）股票。

Which Cathie Wood Pick Is Rated a ‘Strong Buy’ by Wall Street?

華爾街被評為“強勁買”的凱茜木片？

Using TipRanks’ Stock Comparison Tool, let's see what Wall Street thinks of Cathie Wood's stock picks.

使用Tipranks的庫存比較工具，讓我們看看華爾街對Cathie Wood的股票選秀的看法。

Out of the four stocks, GitLab stock has a Strong Buy consensus rating among analysts.

在四個股票中，Gitlab股票在分析師之間的共識評級很高。

CRISPR Therapeutics shares have a Hold rating with seven Buys, 14 Holds, and two Sells. The average CRISPR stock price target of $37.34 suggests about 22% downside potential.

CRISPR Therapeutics股票的評級為七個購買，14個持有和2個賣出。 CRISPR股票目標價為37.34美元，表明下行潛力約為22％。

Cathie Wood Dumps PATH Stock

Cathie Wood傾倒路徑庫存

Cathie Wood's ARK ETFs on Thursday reduced their exposure to UiPath (NYSE:PATH) stock as her ARK Next Generation Internet ETF (ARKW) sold 900,000 shares of the automation software company.

Cathie Wood的ARK ETF週四減少了他們對Uipath（NYSE：PATH）股票的接觸，因為她的方舟下一代Internet ETF（ARKW）出售了90萬股自動化軟件公司的股票。

The move follows the recently reported mixed Q4 results and soft guidance from UiPath.

此舉遵循最近報導的Q4結果和Uipath的軟指導。

The reduced exposure comes after a period of increased investment in UiPath. Earlier this week, the ARKK ETF plowed $10 million into UiPath stock.

在對Uipath的投資增加之後，暴露量減少。本週早些時候，ARKK ETF向Uipath股票耕種了1000萬美元。

According to the SEC filing, the ARKK ETF and the ARKW ETF collectively sold 1,101,216 shares of PATH stock for $13 million.

根據SEC文件，ARKK ETF和ARKW ETF共同出售了1,101,216股Path Stock，售價為1300萬美元。

The sell-off in UiPath stock is part of a broader trend in Cathie Wood's ARK ETFs, which have been selling off some of their largest holdings in recent months.

Uipath股票的拋售是Cathie Wood的ARK ETF的更廣泛趨勢的一部分，Cathie Wood的ARK ETF近幾個月來一直出售其最大的持股。

This sell-off comes amid macro uncertainties and tariff wars that are dragging down crypto markets and U.S. stocks. However, some of the deepest cuts in U.S. stocks over the past 12 months make them attractive bargain picks.

這種拋售是出於宏觀不確定性和關稅戰爭而拖延加密市場和美國股票的原因。但是，在過去的12個月中，美國股票中一些最深的削減使它們有吸引力的討價還價。

See more PATH analyst ratings

查看更多路徑分析師評分